A big drugmaker is backing away from a plan to triple the price of a lifesaving cancer drug after facing a public backlash

FILE PHOTO: Pharmaceutical tablets and capsules are arranged on a table in this picture illustration taken in Ljubljana August 20, 2014.  REUTERS/Srdjan Zivulovic /File PhotoThomson Reuters

  • Drugmaker Pharmacyclics had tripled the cost of a lifesaving cancer blood treatment when it introduced a new version of the pill.
  • The new price tag faced criticism from cancer doctors who were concerned about how this would impact how they dosed patients with the drug. 
  • Last week, Pharmacyclics reversed its decision to take the initial version of the drug off the market, giving patients and doctors a lower-cost option. 

The maker of a lifesaving blood cancer treatment planned to triple the cost of the drug — but it’s backing down after pressure from doctors. 

The drug, Imbruvica, treats serious forms of blood cancer such as leukemia and lymphoma. Developed by Pharmacyclics in conjunction with Johnson & Johnson’s Janssen arm, it has increased survival rates especially in high-risk patients and most patients treated with the drug show favorable outcomes.

See the rest of the story at Business Insider

NOW WATCH: BlackRock’s $ 1.8 trillion bond chief shares an epiphany he had that reshaped his entire economic outlook

See Also:

SEE ALSO: NYC is better known for banking than biotechs — but billions in investments are flowing in to change that

Post Author: martin

Martin is an enthusiastic programmer, a webdeveloper and a young entrepreneur. He is intereted into computers for a long time. In the age of 10 he has programmed his first website and since then he has been working on web technologies until now. He is the Founder and Editor-in-Chief of BriefNews.eu and PCHealthBoost.info Online Magazines. His colleagues appreciate him as a passionate workhorse, a fan of new technologies, an eternal optimist and a dreamer, but especially the soul of the team for whom he can do anything in the world.

Leave a Reply

Your email address will not be published. Required fields are marked *